Gossamer Bio (GOSS) Competitors

Gossamer Bio (NASDAQ:GOSS) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.

Do analysts prefer GOSS or SCPH?

Gossamer Bio presently has a consensus price target of $7.65, suggesting a potential upside of 912.71%. scPharmaceuticals has a consensus price target of $19.33, suggesting a potential upside of 312.22%. Given Gossamer Bio's higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than scPharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
scPharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is GOSS or SCPH more profitable?

Gossamer Bio has a net margin of 0.00% compared to scPharmaceuticals' net margin of -403.22%. scPharmaceuticals' return on equity of -97.18% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	N/A	-944.79%	-67.76%
scPharmaceuticals	-403.22%	-97.18%	-49.59%

Which has more volatility & risk, GOSS or SCPH?

Gossamer Bio has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.

Which has better earnings & valuation, GOSS or SCPH?

scPharmaceuticals has higher revenue and earnings than Gossamer Bio. scPharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	N/A	N/A	-$179.82M	-$1.39	-0.54
scPharmaceuticals	$13.59M	12.44	-$54.81M	-$1.42	-3.30

Does the media prefer GOSS or SCPH?

In the previous week, Gossamer Bio had 13 more articles in the media than scPharmaceuticals. MarketBeat recorded 15 mentions for Gossamer Bio and 2 mentions for scPharmaceuticals. Gossamer Bio's average media sentiment score of 0.31 beat scPharmaceuticals' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	2 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
scPharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer GOSS or SCPH?

scPharmaceuticals received 12 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 66.10% of users gave scPharmaceuticals an outperform vote while only 65.16% of users gave Gossamer Bio an outperform vote.

Company	Underperform	Outperform
Gossamer Bio	Outperform Votes 144 65.16%	Underperform Votes 77 34.84%
scPharmaceuticals	Outperform Votes 156 66.10%	Underperform Votes 80 33.90%

Do institutionals and insiders hold more shares of GOSS or SCPH?

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by insiders. Comparatively, 4.7% of scPharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Gossamer Bio beats scPharmaceuticals on 9 of the 17 factors compared between the two stocks.